Yufeng Xi1
Yujia Wang1,2*- 1Department of Neonatology, Chengdu Women’s and Children’s Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
- 2Department of Dermatology, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
Insulin like growth factor 2 mRNA binding protein 1 (IGF2BP1) belongs to a conserved RNA binding protein family, including IGF2BP1, IGF2BP2, and IGF2BP3. IGF2BPs contain six important domains, including two N-terminal RNA recognition binding domains and four C-terminal ribonucleoprotein-K homology. This structural feature allows IGF2BPs to bind to a variety of target mRNAs and then regulate the expression level of target genes at the post-transcriptional level (Wächter et al., 2013). IGF2BP1 is highly expressed in a variety of malignant tumors, and it is inclined to be considered as an oncogene. IGF2BP1 is involved in the proliferation, adhesion, and migration in tumor development (Bell et al., 2013). Since Elcheva et al. (2008) first reported the role of IGF2BP1 in melanoma in 2008, we note that IGF2BP1 plays an important role in melanoma resistance and hereby summarize the latest research on it.
It has been reported that IGF2BP1 may serve as a prognostic marker in melanoma, on account of IGF2BP1 being overexpressed in metastatic melanoma, which leads to resistance to chemotherapeutic agents (Craig and Spiegelman, 2012; Fortis et al., 2017). Although BRAF inhibitors significantly improve survival in patients with metastatic melanoma, most patients relapse less than a year after treatment (Robert et al., 2015). Inhibition of IGF2BP1 can enhance the role of BRAF inhibitors and BRAF-MEK inhibitors in BRAFV600E melanoma. Besides, knockout of IGF2BP1 alone is sufficient to reduce the tumorigenicity of vemurafenib-resistant melanoma (Kim et al., 2018). Archita Ghoshal et al. reported that the RNA-binding protein IGF2BP1 played a critical role in melanoma metastasis. The suppression of IGF2BP1 did not inhibit primary tumor formation, but lung metastasis has been significantly inhibited. It has been proposed for the first time that RNA-binding protein played a role in EV-mediated promotion of metastasis. EVs (extracellular vesicles) from IGF2BP1-overexpressed melanoma cells further accelerated EV-induced metastasis. And EVs from IGF2BP1 knockdown melanoma cells affected the metastasis microenvironment via inhibiting fibronectin deposition and CD45+ cell accumulation in the lung; thus, EVs from IGF2BP1 knockdown melanoma cells cannot promote metastasis. IGF2BP1 was closely related to the regulation of the cargo of EVs, thus affecting the pro-metastatic function of melanoma-derived EVs, which may open a new way for the development of potential inhibitors for cancer treatment (Ghoshal et al., 2019). In addition, the conservative interaction between THOR and IGF2BP1 has been reported, and it has been shown that THOR was conducive to the mRNA stabilization activities of IGF2BP1 in the zebrafish model of melanoma (Hosono et al., 2017). p62 interacted with IGF2BP1 via the PB1 domain in UACC-62 cells (melanoma cell lines) and then controlled the mRNA stability of FERMT2 and multiple pro-metastatic factors (EHMT2, CD2AP, TOP2A, FLOT1, OGFOD1, and NCEH1) (Karras et al., 2019). Inhibition of IGF2BP1 can reduce the stability of PKCα mRNA, the expression of PKCα protein, and MAPK/ERK activation to improve overall survival in melanoma (Mahapatra et al., 2019). As for IGF2BP1 inhibitor, BTYNB could widely inhibit the activity of IGF2BP1 in a variety of tumors. It disrupts IGF2PB1-RNA binding to inhibit post-transcriptional “super”-enhancer action in E2F-driven gene expression (Müller et al., 2020). When combined with several common chemotherapeutic drugs and CDK inhibitors, BTYNB has a synergistic effect on the inhibition of the proliferation of neuroblastoma cells (Biegel et al., 2021). At present, chemotherapy drugs are widely used in clinical practice and CDK inhibitors are also approved for marketing, IGF2BP1 inhibitors combined with existing clinical drugs may lead to higher efficiency and lower drug resistance and toxicity, thus bringing better therapeutic effects for patients. Another IGF2BP1 inhibitor termed “7773” can directly bind IGF2BP1 and inhibit its binding to Kras RNA (Wallis et al., 2022). Kras is a common mutation site in tumors, which is difficult to target. So far, no Kras target drug has been approved for clinical use. Therefore, the IGF2BP1 inhibitor “7773” has potential clinical value. In the treatment of melanoma, BTYNB was identified as an effective and selective inhibitor of IGF2BP1 binding to c-myc mRNA to reduce melanoma cell proliferation (Mahapatra et al., 2017). IGF2BP1 stabilized MITF mRNA and increased its expression and its transcriptional activity, which was mediated by counteracting the miR-340–mediated degradation of MITF mRNA (Goswami et al., 2015). Many studies have shown that IGF2BP1 inhibitors have potential clinical application, whether used alone or in combination with other drugs.
Those findings suggested that IGF2BP1 may be a new target treatment of melanoma to overcome drug resistance. IGF2BP1 can promote the overexpression of several carcinogenic proteins by binding and stabilizing its mRNA. BTYNB, a new IGF2BP1 inhibitor, can selectively and effectively inhibit IGF2BP1 binding to c-myc mRNA. Small molecule inhibitors can affect the binding of RBP and mRNA to affect the stability of mRNA, which may provide a new way for the development of cancer drugs. Meanwhile, IGF2BP1 was closely related to the regulation of the cargo of EVs, which had the potential to become a new therapy related to RBP targeted therapy. In addition, some reports described the interaction between RBPs and miRNAs/lncRNAs, where RBPs interfere with miRNA/lncRNAs function, thus highlighting a new pattern of post-transcriptional regulation of gene expression (Kedde and Agami, 2008; Ferrè et al., 2016). It has been reported that IGF2BP1 interfered with the function of miR-183, influencing the stabilization of βTrCP1 mRNA in 293T cells (Elcheva et al., 2009). IGF2BP1 stabilized MITF mRNA and increased its expression and its transcriptional activity in melanoma, which was mediated by counteracting the miR-340–mediated degradation of MITF mRNA (Goswami et al., 2015). LncRNA THOR can regulate the mRNA stabilization activities of IGF2BP1 via binding to IGF2BP1. It is speculated that the combination of lncRNAs/miRNAs and RBP to regulate mRNA stability/gene expression provides a new idea for tumor treatment, and the development of small molecule inhibitors for RBP offers new possibilities for cancer therapy.
Author Contributions
Contributions: (I) conception and design: YX; (II) administrative support: YW; (III) manuscript writing: all authors; (IV) final approval of manuscript: all authors.
Funding
This research was supported by grants from the Fundamental Research Funds of Science and Technology Department of Sichuan Province (Grant Nos. 2019YJ0648).
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Bell, J. L., Wächter, K., Mühleck, B., Pazaitis, N., Köhn, M., Lederer, M., et al. (2013). Insulin-like Growth Factor 2 mRNA-Binding Proteins (IGF2BPs): Post-transcriptional Drivers of Cancer Progression? Cell Mol. Life Sci. 70, 2657–2675. doi:10.1007/s00018-012-1186-z
Biegel, J. M., Dhamdhere, M., Gao, S., Gowda, C. P., Kawasawa, Y. I., and Spiegelman, V. S. (2021). Inhibition of the mRNA-Binding Protein IGF2BP1 Suppresses Proliferation and Sensitizes Neuroblastoma Cells to Chemotherapeutic Agents. Front. Oncol. 11, 608816. doi:10.3389/fonc.2021.608816
Craig, E. A., and Spiegelman, V. S. (2012). Inhibition of Coding Region Determinant Binding Protein Sensitizes Melanoma Cells to Chemotherapeutic Agents. Pigment. Cell Melanoma Res. 25, 83–87. doi:10.1111/j.1755-148X.2011.00921.x
Elcheva, I., Goswami, S., Noubissi, F. K., and Spiegelman, V. S. (2009). CRD-BP Protects the Coding Region of betaTrCP1 mRNA from miR-183-Mediated Degradation. Mol. Cell 35, 240–246. doi:10.1016/j.molcel.2009.06.007
Elcheva, I., Tarapore, R. S., Bhatia, N., and Spiegelman, V. S. (2008). Overexpression of mRNA-Binding Protein CRD-BP in Malignant Melanomas. Oncogene 27, 5069–5074. doi:10.1038/onc.2008.141
Ferrè, F., Colantoni, A., and Helmer-Citterich, M. (2016). Revealing Protein-lncRNA Interaction. Brief. Bioinform 17, 106–116. doi:10.1093/bib/bbv031
Fortis, S. P., Anastasopoulou, E. A., Voutsas, I. F., Baxevanis, C. N., Perez, S. A., and Mahaira, L. G. (2017). Potential Prognostic Molecular Signatures in a Preclinical Model of Melanoma. Anticancer Res. 37, 143–148. doi:10.21873/anticanres.11299
Ghoshal, A., Rodrigues, L. C., Gowda, C. P., Elcheva, I. A., Liu, Z., Abraham, T., et al. (2019). Extracellular Vesicle-dependent Effect of RNA-Binding Protein IGF2BP1 on Melanoma Metastasis. Oncogene 38, 4182–4196. doi:10.1038/s41388-019-0797-3
Goswami, S., Tarapore, R. S., Poenitzsch Strong, A. M., TeSlaa, J. J., Grinblat, Y., Spiegelman, V., et al. (2015). MicroRNA-340-mediated Degradation of Microphthalmia-Associated Transcription Factor (MITF) mRNA Is Inhibited by Coding Region Determinant-Binding Protein (CRD-BP). J. Biol. Chem. 290, 384–395. doi:10.1074/jbc.M114.590158
Hosono, Y., Niknafs, Y. S., Prensner, J. R., Iyer, M. K., Dhanasekaran, S. M., Mehra, R., et al. (2017). Oncogenic Role of THOR, a Conserved Cancer/Testis Long Non-coding RNA. Cell 171, 1559–1572. e20. doi:10.1016/j.cell.2017.11.040
Karras, P., Riveiro-Falkenbach, E., Cañón, E., Tejedo, C., Calvo, T. G., Martínez-Herranz, R., et al. (2019). p62/SQSTM1 Fuels Melanoma Progression by Opposing mRNA Decay of a Selective Set of Pro-metastatic Factors. Cancer Cell 35, 46–63. e10. doi:10.1016/j.ccell.2018.11.008
Kedde, M., and Agami, R. (2008). Interplay between microRNAs and RNA-Binding Proteins Determines Developmental Processes. Cell Cycle 7, 899–903. doi:10.4161/cc.7.7.5644
Kim, T., Havighurst, T., Kim, K., Albertini, M., Xu, Y. G., and Spiegelman, V. S. (2018). Targeting Insulin-like Growth Factor 2 mRNA-Binding Protein 1 (IGF2BP1) in Metastatic Melanoma to Increase Efficacy of BRAFV600E Inhibitors. Mol. Carcinog. 57, 678–683. doi:10.1002/mc.22786
Mahapatra, L., Andruska, N., Mao, C., Gruber, S. B., Johnson, T. M., Fullen, D. R., et al. (2019). Protein Kinase C-α Is Upregulated by IMP1 in Melanoma and Is Linked to Poor Survival. Melanoma Res. 29, 539–543. doi:10.1097/CMR.0000000000000558
Mahapatra, L., Andruska, N., Mao, C., Le, J., and Shapiro, D. J. (2017). A Novel IMP1 Inhibitor, BTYNB, Targets C-Myc and Inhibits Melanoma and Ovarian Cancer Cell Proliferation. Transl. Oncol. 10, 818–827. doi:10.1016/j.tranon.2017.07.008
Müller, S., Bley, N., Busch, B., Glaß, M., Lederer, M., Misiak, C., et al. (2020). The Oncofetal RNA-Binding Protein IGF2BP1 Is a Druggable, Post-transcriptional Super-enhancer of E2F-Driven Gene Expression in Cancer. Nucleic acids Res. 48, 8576–8590. doi:10.1093/nar/gkaa653
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., et al. (2015). Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. N. Engl. J. Med. 372, 30–39. doi:10.1056/NEJMoa1412690
Wächter, K., Köhn, M., Stöhr, N., and Hüttelmaier, S. (2013). Subcellular Localization and RNP Formation of IGF2BPs (IGF2 mRNA-Binding Proteins) Is Modulated by Distinct RNA-Binding Domains. Biol. Chem. 394 (8), 1077–1090. doi:10.1515/hsz-2013-0111
Keywords: IGF2BP1, drug resistance, melanoma, RNA binding protein, mRNA stabilization
Citation: Xi Y and Wang Y (2022) IGF2BP1, a New Target to Overcome Drug Resistance in Melanoma?. Front. Pharmacol. 13:947363. doi: 10.3389/fphar.2022.947363
Received: 18 May 2022; Accepted: 22 June 2022;
Published: 22 July 2022.
Edited by:
Vladimir Spiegelman, Penn State Milton S. Hershey Medical Center, United StatesReviewed by:
Nadine Bley, University of Halle, GermanyCopyright © 2022 Xi and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yujia Wang, MTU4ODE0MjQ5OTdAMTYzLmNvbQ==